Literature DB >> 33215807

ECT2 promotes lung adenocarcinoma progression through extracellular matrix dynamics and focal adhesion signaling.

Zeinab Kosibaty1,2, Yoshihiko Murata1, Yuko Minami3, Masayuki Noguchi1, Noriaki Sakamoto1.   

Abstract

Lung adenocarcinoma (LAC) is the most prevalent form of lung cancer. Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor that has been implicated in oncogenic and malignant phenotypes of LAC. Here, we identified an oncogenic role of ECT2 in the extracellular matrix (ECM) dynamics of LAC cells. We showed that suppression of ECT2 decreased adhesion and spreading of LAC cells on ECM components. Morphologically, ECT2-depleted cells exhibited a rounded shape and cytoskeletal changes. Examination of transcriptional changes by RNA sequencing revealed a total of 1569 and 828 genes whose expressions were altered (absolute fold change and a difference of >2 fold) in response to suppression of ECT2 in two LAC cells (Calu-3 and NCI-H2342), respectively, along with 298 genes that were common to both cell lines. Functional enrichment analysis of common genes demonstrated a significant enrichment of focal adhesions. In accord with this observation, we found that ECT2 suppression decreased the expression level of proteins involved in focal adhesion signaling including focal adhesion kinase (FAK), Crk, integrin β1, paxillin, and p130Cas. FAK knockdown leads to impaired cell proliferation, adhesion, and spreading of LAC cells. Moreover, in LAC cells, ECT2 binds to and stabilizes FAK and is associated with the formation of the focal adhesions. Our findings provide new insights into the underlying role of ECT2 in cell-ECM dynamics during LAC progression and suggest that ECT2 could be a promising therapeutic avenue for lung cancer.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  ECT2; RNA sequencing; extracellular matrix; focal adhesion; lung adenocarcinoma

Year:  2020        PMID: 33215807     DOI: 10.1111/cas.14743

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  5 in total

1.  The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.

Authors:  Chun Liu; Chenxi Hu; Ting Chen; Yanting Jiang; Xin Zhang; Hongyu Liu; Yuan Wang; Zhi Li; Kaiyuan Hui; Xiaodong Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-07       Impact factor: 4.322

2.  RS1 gene is a novel prognostic biomarker for lung adenocarcinoma.

Authors:  Tao Zhang; Guowei Cheng; Ping Chen; Yue Peng; Lei Liu; Runze Li; Bin Qiu
Journal:  Thorac Cancer       Date:  2022-05-15       Impact factor: 3.223

3.  A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma.

Authors:  Wenhao Ouyang; Yupeng Jiang; Shiyi Bu; Tiantian Tang; Linjie Huang; Ming Chen; Yujie Tan; Qiyun Ou; Luhui Mao; Yingjie Mai; Herui Yao; Yunfang Yu; Xiaoling Lin
Journal:  Front Cell Dev Biol       Date:  2022-01-24

4.  Establishing a Macrophage Phenotypic Switch-Associated Signature-Based Risk Model for Predicting the Prognoses of Lung Adenocarcinoma.

Authors:  Jun Chen; Chao Zhou; Ying Liu
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

5.  Ovarian carcinoma immunoreactive antigen domain 2 controls mitochondrial apoptosis in lung adenocarcinoma.

Authors:  Jeongmin Hong; Aya Shiba-Ishii; Yunjung Kim; Masayuki Noguchi; Noriaki Sakamoto
Journal:  Cancer Sci       Date:  2021-10-18       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.